Share Capital Reduction Effective
Updated : 07:02
PRESS RELEASE
Share Capital Reduction Effective
Guildford, UK - 18 November 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that, further to its announcements on 1 October and 19 October 2020, the High Court of England and Wales sanctioned on 10 November 2020 the Company's application for its Capital Reduction.
On 17 November 2020 the Registrar of Companies registered the order of the High Court confirming the Capital Reduction and the related statement of capital approved by the High Court, whereupon the Capital Reduction became effective.
The Company confirms that, following the Capital Reduction, the issued share capital of the Company comprises 48,717,776 ordinary shares of 1p each and there are no shares held in treasury. The total number of voting rights in the Company is therefore 48,717,776.
Terms used but not defined in this announcement are as defined in the Company's announcement of 1 October 2020.
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 402 975 |
Miroslav Reljanović (Executive Chairman) | |
Richard Barfield (Chief Financial Officer) | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Freddie Barnfield / Huw Jeremy (Nominated Adviser) | |
James Black (Broker) | |
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Sue Stuart | ergomed@consilium-comms.com |
Matthew Neal / Olivia Manser |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.